SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-21-144962
Filing Date
2021-04-30
Accepted
2021-04-30 16:03:05
Documents
10
Period of Report
2021-06-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A d150509ddef14a.htm DEF 14A 338902
2 GRAPHIC g150509g02c48.jpg GRAPHIC 31849
3 GRAPHIC g150509g09v73.jpg GRAPHIC 1338
4 GRAPHIC g150509g20r24.jpg GRAPHIC 1122
5 GRAPHIC g150509g35o50.jpg GRAPHIC 888
6 GRAPHIC g150509g52c82.jpg GRAPHIC 1508
7 GRAPHIC g150509g81o20.jpg GRAPHIC 2114
8 GRAPHIC g150509g86y42.jpg GRAPHIC 1484
9 GRAPHIC g150509g95y44.jpg GRAPHIC 1626
10 GRAPHIC g150509spvii01.jpg GRAPHIC 1042
  Complete submission text file 0001193125-21-144962.txt   400436
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39614 | Film No.: 21877722
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences